Wahab N, Toss M, Miligy I, Jahanifar M, Atallah N, Lu W
NPJ Precis Oncol. 2023; 7(1):122.
PMID: 37968376
PMC: 10651910.
DOI: 10.1038/s41698-023-00472-y.
Chen Y, Li H, Janowczyk A, Toro P, Corredor G, Whitney J
NPJ Breast Cancer. 2023; 9(1):40.
PMID: 37198173
PMC: 10192429.
DOI: 10.1038/s41523-023-00545-y.
Loi S, Salgado R, Adams S, Pruneri G, Francis P, Lacroix-Triki M
NPJ Breast Cancer. 2022; 8(1):3.
PMID: 35017545
PMC: 8752727.
DOI: 10.1038/s41523-021-00362-1.
Rantalainen M, Klevebring D, Lindberg J, Ivansson E, Rosin G, Kis L
Sci Rep. 2016; 6:38037.
PMID: 27901097
PMC: 5128815.
DOI: 10.1038/srep38037.
Dobbs J, Mueller J, Krishnamurthy S, Shin D, Kuerer H, Yang W
Breast Cancer Res. 2015; 17:105.
PMID: 26290094
PMC: 4545917.
DOI: 10.1186/s13058-015-0617-9.
Incidence and prediction of invasive disease and nodal metastasis in preoperatively diagnosed ductal carcinoma in situ.
Osako T, Iwase T, Ushijima M, Horii R, Fukami Y, Kimura K
Cancer Sci. 2014; 105(5):576-82.
PMID: 24533797
PMC: 4317837.
DOI: 10.1111/cas.12381.
Relationship between morphological features and kinetic patterns of enhancement of the dynamic breast magnetic resonance imaging and clinico-pathological and biological factors in invasive breast cancer.
Fernandez-Guinea O, Andicoechea A, Gonzalez L, Gonzalez-Reyes S, Merino A, Hernandez L
BMC Cancer. 2010; 10:8.
PMID: 20064215
PMC: 2819997.
DOI: 10.1186/1471-2407-10-8.
An overview of prognostic factors for long-term survivors of breast cancer.
Soerjomataram I, Louwman M, Ribot J, Roukema J, Coebergh J
Breast Cancer Res Treat. 2007; 107(3):309-30.
PMID: 17377838
PMC: 2217620.
DOI: 10.1007/s10549-007-9556-1.
Prognostic factors in breast cancer: current and new predictors of metastasis.
Hayes D, Isaacs C, Stearns V
J Mammary Gland Biol Neoplasia. 2002; 6(4):375-92.
PMID: 12013528
DOI: 10.1023/a:1014778713034.
Spectral morphometric characterization of breast carcinoma cells.
Barshack I, Kopolovic J, Malik Z, Rothmann C
Br J Cancer. 1999; 79(9-10):1613-9.
PMID: 10188915
PMC: 2362715.
DOI: 10.1038/sj.bjc.6690257.
Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer.
Niskanen E, Blomqvist C, Franssila K, Hietanen P, Wasenius V
Br J Cancer. 1997; 76(7):917-22.
PMID: 9328152
PMC: 2228069.
DOI: 10.1038/bjc.1997.484.
Vimentin expression in 98 breast cancers with medullary features and its prognostic significance.
Holck S, Pedersen L, Schiodt T, Zedeler K, Mouridsen H
Virchows Arch A Pathol Anat Histopathol. 1993; 422(6):475-9.
PMID: 8392769
DOI: 10.1007/BF01606456.
Prognostic significance of a formalin-resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-S1.
Kreipe H, Alm P, Olsson H, Hauberg M, Fischer L, Parwaresch R
Am J Pathol. 1993; 142(2):651-7.
PMID: 8094598
PMC: 1886747.
Monoclonal antibody BrE-3 participation in a multivariate prognostic model for infiltrating ductal carcinoma of the breast.
Chan C, Baratta F, Ozzello L, Ceriani R
Breast Cancer Res Treat. 1994; 30(3):243-61.
PMID: 7981443
DOI: 10.1007/BF00665966.
Prognostic value of proliferating cell nuclear antigen and c-erbB-2 compared with conventional histopathological factors in breast cancer.
Schonborn I, Zschiesche W, Minguillon C, Spitzer E, Mohner M, EBELING K
J Cancer Res Clin Oncol. 1995; 121(2):115-22.
PMID: 7883773
DOI: 10.1007/BF01202223.
Determining factors which predict response to primary medical therapy in breast cancer using a single fine needle aspirate with immunocytochemical staining and flow cytometry.
Fernando I, Powles T, Dowsett M, Ashley S, McRobert L, Titley J
Virchows Arch. 1995; 426(2):155-61.
PMID: 7757286
DOI: 10.1007/BF00192637.
Tumor nuclear grade, estrogen receptor, and progesterone receptor: their value alone or in combination as indicators of outcome following adjuvant therapy for breast cancer.
Fisher B, Fisher E, Redmond C, Brown A
Breast Cancer Res Treat. 1986; 7(3):147-60.
PMID: 3535933
DOI: 10.1007/BF01806245.
Proliferative index of breast carcinoma by thymidine labeling: prognostic power independent of stage, estrogen and progesterone receptors.
Meyer J, Province M
Breast Cancer Res Treat. 1988; 12(2):191-204.
PMID: 3242648
DOI: 10.1007/BF01805940.
An assessment of extensive intraductal component as a risk factor for local recurrence after breast-conserving therapy.
Jacquemier J, Kurtz J, Amalric R, BRANDONE H, AYME Y, Spitalier J
Br J Cancer. 1990; 61(6):873-6.
PMID: 2164836
PMC: 1971685.
DOI: 10.1038/bjc.1990.195.
Node negative breast cancer.
OReilly S, Richards M
BMJ. 1990; 300(6721):346-8.
PMID: 2106982
PMC: 1662130.
DOI: 10.1136/bmj.300.6721.346.